Navigation Links
The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
Date:2/25/2008

SAN DIEGO, Feb. 25 /PRNewswire/ -- Speid & Associates, a San Diego-based regulatory affairs and drug development consultancy, is hosting a six session Webinar series on diabetes and related metabolic diseases during the months of March and April. Speakers will include former Food and Drug Administration officials Dr. Alexander Fleming and Dr. Ray Lipicky, as well as a distinguished list of other guest speakers and panelists.

Researchers and companies involved in diabetes therapeutic development are finding a complex array of possible targets across diabetes (both type 1, type 2), the metabolic syndrome, and the complications and causes of diabetes. This translates into a complex pathway for therapeutic development and registration with many potential pitfalls along the way. The webinar series will promote discussion on the inter-related issues of diabetes/metabolic therapeutic development and registration.

Dr. Speid said, "I am delighted that the series will feature such a stellar list of speakers, to address these important topics and issues." Dr. Alexander Fleming, ex-FDA (formerly headed diabetes drug review) said, "There is no more active and controversial therapeutic development area than for diabetes drugs. I look forward to discussing the implications of the ACCORD trial and a number of other timely topics."

For many years, Dr. Ray Lipicky headed FDA's Division of Cardiorenal Drug Products. Among his many drug approvals was the first and essentially only approval of treatments for a diabetic complication. The participation of Drs. Lipicky and Fleming in this series mirrors the convergence of cardiovascular and metabolic therapeutics at multiple levels -- pathophysiology, drug targets, trial design, and clinical disciplines.

Speid & Associates, Inc. is a regulatory affairs and drug development consultancy based in San Diego, Calif. The firm, founded in 2004 by Dr. Lorna Speid, Ph.D., assists life science companies at various stages in the drug development process. Speid's services, which vary from building global regulatory strategies to conducting due diligence for possible drug acquisitions, save large and small pharmaceutical firms from costly mistakes. Dr. Speid began her career as a pharmacist in the UK, after which she completed a Ph.D. at the Centre for Medicines Research International, into the Safety Assessment of Medicines, Pre and Post Marketing. Before forming her own consultancy, Dr. Speid worked for Sanofi Winthrop in the UK, Ciba Geigy and Novartis in Switzerland (HQ). Dr. Speid also worked for a number of small pharmaceutical companies, two of them at the Vice President level. For more information, see http://www.sndtm.com.

Further information regarding the webinar series is available at: http://www.sndtm.com/webinar.html as well as sign up instructions.

Telephone 858 793 1295. Email lspeid@sndtm.com.


'/>"/>
SOURCE Speid & Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
2. Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits
3. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
4. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
5. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
6. International Diabetes Experts Call for Stepped-Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact
7. World Think Tank on Type 1 Diabetes Meets in Miami
8. New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays
9. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
10. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
11. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... It is well established ... however, the broad application of this cellular target engagement concept to drug discovery ... Cell-based thermal stabilization assays are valuable methods for particular applications, but they can ...
(Date:4/21/2017)... ... April 21, 2017 , ... The impressively ... focus of researchers, engineers, product developers, and industry suppliers gathered last week for ... SPIE, the international society for optics and photonics , the event drew ...
(Date:4/20/2017)... TX; Ultrecht, Netherlands (PRWEB) , ... April 20, ... ... Qafis Biometrics Technology today announced their strategic partnership to offer a full ... digital identity authentication, a comprehensive suite of biometric products and the ground-breaking proactive ...
(Date:4/20/2017)... /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" ... Liver Congress ("ILC") 2017 of the European Association for the ... on the positive effects of PBI-4050 on reduction of ... metabolic syndrome. ... Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of Prometic "This ...
Breaking Biology Technology:
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
Breaking Biology News(10 mins):